However, accumulating clinical evidence reveals that wild-type RHOA (WT-RHOA) is frequently hyperactivated in human cancers [4, 6, 7], with particularly elevated activity observed at invasive tumor fronts and metastatic sites [8], suggesting alternative activation mechanisms beyond genetic mutations. This evidence concerns the gene RHOA and neoplasm.